Cisplatin DNA Damage: How It Works to Fight Cancer

Cisplatin kills cancer cells by forming chemical bonds directly on their DNA, creating structural damage so severe that the cell can no longer copy its genetic material or read its genes properly. When the damage is extensive enough, the cell triggers its own death. This mechanism has made cisplatin one of the most widely used chemotherapy drugs since the 1970s, effective against cancers of the lung, bladder, ovaries, testes, and head and neck, among others. But the story beneath that simple description involves an intricate chain of chemistry, cellular defense, and biological tug-of-war between drug and tumor.

A Lucky Accident in the Lab

Cisplatin’s anticancer properties were discovered by accident. In 1965, a biophysicist named Barnett Rosenberg was studying how electric fields affect the growth of bacteria. He noticed that the bacteria stopped dividing but kept growing, swelling to roughly 300 times their normal size. It turned out that the platinum electrodes in his apparatus were releasing a compound into the growth medium, and that compound was cisplatin. Rosenberg reasoned that if a platinum compound could block bacterial cell division, it might also stop the runaway division of tumor cells. He was right, and cisplatin entered clinical use for cancer within about a decade.¹

Getting Inside the Cell and Switching On

Cisplatin is administered intravenously as a stable, neutral molecule. It crosses cell membranes through two routes: it can slip through passively, following concentration gradients, or it can ride in on a copper transport protein called CTR1 that normally ferries copper ions into cells.² Once inside, the chemistry of the cell’s interior changes everything. The chloride concentration inside a cell is much lower than in the bloodstream, and this shift causes water molecules to replace the chloride groups on the cisplatin molecule. The result is a positively charged, highly reactive form of the drug that readily latches onto DNA.

This activation step matters because it explains something patients sometimes wonder about: why cisplatin is relatively stable during its trip through the bloodstream but becomes aggressive once it reaches a cell’s interior. The high chloride concentration of blood plasma keeps the drug in its inert form. Only when it enters the low-chloride environment inside the cell does it “switch on.”

How Cisplatin Damages DNA

The activated drug targets a specific chemical site on DNA’s building blocks: the nitrogen atom at the N7 position on purine bases, particularly guanine. Because cisplatin has two reactive arms, it can grab onto two neighboring bases at the same time, forming what chemists call a crosslink. The most common product is a link between two adjacent guanine bases on the same strand of DNA.³ A second common type links an adjacent adenine and guanine. Less frequently, cisplatin bridges the two complementary strands of the double helix, creating an interstrand crosslink.⁴

These crosslinks are not cosmetic scratches. They warp the physical shape of the double helix. The major guanine-guanine crosslink bends the DNA strand toward the major groove by roughly 35 to 40 degrees and partially unwinds the helix at the damage site.⁵ This bending and unwinding is consistent regardless of the surrounding DNA sequence, which means the structural disruption is a reliable consequence of cisplatin binding no matter where in the genome it lands.⁶

Stalling the Machinery That Reads and Copies DNA

The structural kink cisplatin creates in the double helix is too bulky for the cell’s normal machinery to read past. When a DNA replication fork, the moving complex that copies the entire genome before a cell divides, encounters a cisplatin crosslink, it grinds to a halt.⁷ Transcription, the process by which specific genes are read to produce proteins, is similarly blocked. A cell that cannot copy its DNA cannot divide, and a cell that cannot transcribe its genes cannot maintain the proteins it needs to survive.

The stalled replication fork is itself a danger signal. It activates checkpoint pathways that force the cell to pause its division cycle and attempt to repair the damage. If repair succeeds, the cell resumes. If it does not, the cell is pushed toward programmed death. Because cancer cells divide far more often than most normal cells, they encounter these replication roadblocks more frequently, which is a large part of why cisplatin preferentially kills tumors over healthy tissue.

How a Protein Shields the Damage From Repair

Cells have powerful DNA repair systems, and their ability to fix cisplatin damage is the single biggest factor in whether a tumor responds to the drug or resists it. But there is an interesting wrinkle: a common nuclear protein called HMGB1 actually helps the drug by interfering with repair. HMGB1 has a strong affinity for the bent, distorted shape that cisplatin creates in DNA. When it binds to a cisplatin lesion, it physically blocks the repair machinery from accessing the damage.⁸

This shielding effect has been confirmed in living cells, not just in test tubes. In mouse fibroblast experiments, overexpression of HMGB1 slowed the repair of cisplatin damage, keeping the lesions in place longer and giving the drug more time to trigger cell death.⁹ This raises a natural question: could HMGB1 levels in a patient’s tumor predict how well cisplatin will work? Researchers have explored this possibility, though it has not yet translated into a routine clinical test.

Triggering Cell Death

When the DNA damage is too extensive for repair, the cell activates apoptosis, its built-in self-destruction program. The key regulator here is the protein p53, sometimes called the “guardian of the genome.” When p53 senses severe DNA damage, it sets off a cascade that ultimately punches holes in the mitochondria, the cell’s energy-producing compartments. Proteins like cytochrome c leak out of the mitochondria into the surrounding cellular fluid, which activates enzymes called caspases that systematically dismantle the cell from the inside.¹⁰

This mitochondrial pathway is the main route by which cisplatin kills cancer cells, and its integrity matters for treatment outcomes. In chemosensitive ovarian cancer cells, cisplatin successfully triggers p53 accumulation at the mitochondria and the release of the death-signaling proteins. In resistant ovarian cancer cells, this process is blocked, often by overactive survival signals that counteract p53.¹¹ Tumors that carry mutations disabling p53 are frequently resistant to cisplatin from the start, which is one reason the drug works far better in some cancers than others.

Why Some Tumors Resist Cisplatin

Resistance to cisplatin is the central clinical problem with the drug. A tumor may respond dramatically at first and then stop responding, or it may never respond at all. The mechanisms break down into a few broad categories.

The most studied resistance pathway involves nucleotide excision repair, the cell’s system for cutting out bulky DNA lesions and patching the gap with fresh DNA. When this repair machinery is overactive in a tumor, cisplatin’s crosslinks are removed before they can stall replication or trigger apoptosis.¹² A landmark study in non-small-cell lung cancer illustrated this starkly: patients whose tumors lacked a key repair protein called ERCC1 benefited substantially from cisplatin-based chemotherapy, while patients whose tumors expressed ERCC1 at high levels saw no survival benefit at all.¹³

A separate line of defense operates before cisplatin even reaches DNA. Inside the cell, the antioxidant molecule glutathione can bind to activated cisplatin and neutralize it. An enzyme family called glutathione S-transferases catalyzes this reaction. Cells with elevated levels of one particular variant confer modest resistance to cisplatin, roughly 1.4 to 1.7 times the normal tolerance.¹⁴ This is a low-level effect on its own, but when combined with overactive DNA repair and defective apoptosis pathways, the cumulative resistance can be formidable.

Epigenetic changes add another layer. In ovarian cancer, for example, researchers have mapped networks where DNA methylation silences tumor-suppressor genes, non-coding RNA molecules alter gene regulation, and histone modifications reshape the accessibility of chromosomes, all contributing to a drug-resistant state that can sustain itself through multiple interlocking feedback loops.¹⁵

The Cost to Healthy Tissue

Cisplatin does not exclusively target cancer. Its DNA-damaging chemistry works on any cell it enters, and certain healthy tissues are especially vulnerable. Kidney damage is the most clinically significant side effect. The kidneys concentrate cisplatin because renal tubular cells express a transporter called OCT2 that actively pulls the drug inside, while the efflux pump that should push it back out does not keep pace.¹⁶ Once inside, cisplatin depletes the cell’s antioxidant defenses, including glutathione and protective enzymes, leading to a surge of reactive oxygen species that damage mitochondria, lipid membranes, and proteins in addition to DNA.¹⁷ Aggressive hydration during treatment helps flush the drug through the kidneys more quickly and remains the primary preventive strategy.

Hearing loss is another well-known consequence. Cisplatin damages the inner ear, affecting the stria vascularis (which maintains the fluid environment of the cochlea), the sensory hair cells, and the spiral ganglion neurons.¹⁸ What makes this side effect particularly insidious is that the platinum compound becomes trapped in the inner ear. Measurements in animal models show that two months after treatment, platinum levels in the blood dropped by about 89%, but levels in the inner ear’s stria vascularis fell by only about half, and in the spiral ganglion by just a quarter.¹⁹ This retention helps explain why hearing loss from cisplatin is usually permanent and can even worsen after treatment ends.

Timing the Dose to the Body Clock

An emerging area of research asks whether the time of day a patient receives cisplatin changes how well it works and how badly it hurts. This idea, called chronotherapy, is grounded in the observation that DNA repair activity fluctuates with the circadian clock. In mouse melanoma models, animals treated in the evening showed faster removal of cisplatin-DNA adducts from healthy tissue and less toxicity than animals treated in the morning, while tumor control remained strong.²⁰ In a mammary carcinoma model, treatment at one circadian time point significantly slowed tumor growth compared to another time point, suggesting that the drug’s anticancer effect itself may be time-dependent.²¹

Human data are still limited. A randomized trial in advanced non-small-cell lung cancer found that chronotherapy and conventional timing produced similar tumor response rates, but the chronotherapy group experienced significantly less severe bone-marrow suppression and less gastrointestinal toxicity.²² If the drug works equally well against the tumor but hits healthy tissue less hard at a particular time of day, that alone could meaningfully improve a patient’s quality of life during treatment. Larger trials are still needed, and the optimal timing may depend on the individual patient’s own circadian rhythm, which complicates standardization.

Combining Cisplatin With Newer Cancer Therapies

Cisplatin is rarely used alone anymore. For decades, combination with other traditional chemotherapy agents has been standard. More recently, interest has shifted toward pairing cisplatin with two newer classes of drugs: PARP inhibitors and immune checkpoint inhibitors.²³

The rationale for PARP inhibitors is straightforward. PARP enzymes help repair single-strand DNA breaks. When a PARP inhibitor blocks this repair pathway while cisplatin is simultaneously generating double-strand crosslinks and other lesions, the cell’s repair capacity is overwhelmed from two directions at once. Recent work in lung adenocarcinoma models has shown that adding a PARP inhibitor to cisplatin activates an innate immune signaling pathway in the tumor, which in turn boosts the effectiveness of immune checkpoint therapy. In mouse models, this triple combination of cisplatin, a PARP inhibitor, and an anti-PD-L1 antibody suppressed tumors most effectively, increasing infiltration of immune cells that attack the cancer.²⁴ The idea is that cisplatin does the initial DNA wrecking, PARP inhibitors prevent the tumor from cleaning up, and immunotherapy rallies the patient’s own immune system to finish the job.

Other Platinum Drugs and Why Cisplatin Remains Relevant

Carboplatin and oxaliplatin, the two other platinum-based drugs in wide clinical use, were developed partly to address cisplatin’s toxicity and resistance problems. They form DNA adducts through a similar general mechanism but differ in their side-effect profiles and in how tumors respond to them. Cells that are highly resistant to cisplatin tend to show cross-resistance to carboplatin, because both drugs form the same types of DNA crosslinks and the same repair pathways remove them. Oxaliplatin is a different story: in cell-line experiments, cisplatin-resistant cells were less than one-tenth as resistant to oxaliplatin, reflecting the different shape of the DNA adduct oxaliplatin creates and the different way the cell’s repair systems recognize it.²⁵

Despite newer options and well-known toxicities, cisplatin remains the backbone of treatment for several cancers, particularly testicular cancer, where cure rates exceed 90% even in advanced disease. Its ability to generate severe, hard-to-repair DNA damage in rapidly dividing cells is unmatched in certain tumor types, and the expanding possibilities of combination therapy are giving this 50-year-old drug a longer runway than many oncologists expected.